Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 174

1.

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P.

Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219.

PMID:
27384348
2.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

3.

Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly.

Roder D, Karapetis CS, Wattchow D, Moore J, Singhal N, Joshi R, Keefe D, Fusco K, Powell K, Eckert M, Price TJ.

Eur J Cancer Care (Engl). 2016 Jun 3. doi: 10.1111/ecc.12515. [Epub ahead of print]

PMID:
27255681
4.

Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry.

Patel D, Townsend AR, Karapetis C, Beeke C, Padbury R, Roy A, Maddern G, Roder D, Price TJ.

Ann Surg Oncol. 2016 Jun 1. [Epub ahead of print]

PMID:
27251133
5.

Group II mGluRs suppress hyperexcitability in mouse and human nociceptors.

Davidson S, Golden JP, Copits BA, Ray PR, Vogt SK, Valtcheva MV, Schmidt RE, Ghetti A, Price TJ, Gereau RW 4th.

Pain. 2016 May 21. [Epub ahead of print]

PMID:
27218869
6.

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.

Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A.

Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414.

PMID:
27179112
7.

Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties.

Pember SO, Mejia GL, Price TJ, Pasteris RJ.

Bioorg Med Chem Lett. 2016 Jun 15;26(12):2965-73. doi: 10.1016/j.bmcl.2016.02.061. Epub 2016 Feb 22.

PMID:
27130358
8.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
9.

Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.

Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG.

Clin Ther. 2016 Jun;38(6):1376-91. doi: 10.1016/j.clinthera.2016.03.023. Epub 2016 Apr 13.

10.

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.

Price TJ, Thavaneswaran S, Burge M, Segelov E, Haller DG, Punt CJ, Arnold D, Karapetis CS, Tebbutt NC, Pavlakis N, Gibbs P, Shapiro JD.

Expert Rev Anticancer Ther. 2016 May;16(5):557-71. doi: 10.1586/14737140.2016.1170594.

PMID:
27010906
11.

Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro.

Dorward HS, Du A, Bruhn MA, Wrin J, Pei JV, Evdokiou A, Price TJ, Yool AJ, Hardingham JE.

J Exp Clin Cancer Res. 2016 Feb 24;35:36. doi: 10.1186/s13046-016-0310-6.

12.

Neuro-oncology family caregivers are at risk for systemic inflammation.

Sherwood PR, Price TJ, Weimer J, Ren D, Donovan HS, Given CW, Given BA, Schulz R, Prince J, Bender C, Boele FW, Marsland AL.

J Neurooncol. 2016 May;128(1):109-18. doi: 10.1007/s11060-016-2083-3. Epub 2016 Feb 23.

PMID:
26907491
13.

Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.

Tomita Y, Karapetis CS, Ullah S, Townsend AR, Roder D, Beeke C, Roy AC, Padbury R, Price TJ.

Acta Oncol. 2016;55(4):480-5. doi: 10.3109/0284186X.2015.1117135. Epub 2016 Feb 15.

PMID:
26878155
14.

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.

Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V.

Br J Cancer. 2016 Mar 1;114(5):505-9. doi: 10.1038/bjc.2015.440. Epub 2016 Feb 11.

PMID:
26867157
15.

Neuroligin 2 regulates spinal GABAergic plasticity in hyperalgesic priming, a model of the transition from acute to chronic pain.

Kim JY, Megat S, Moy JK, Asiedu MN, Mejia GL, Vagner J, Price TJ.

Pain. 2016 Jun;157(6):1314-24. doi: 10.1097/j.pain.0000000000000513.

PMID:
26859820
16.

Human intestinal spirochetosis and its relationship to sessile serrated adenomas in an Australian population.

Young JP, Price TJ, Moore J, Ruszkiewicz AR.

Pathol Res Pract. 2015 Sep 8. pii: S0344-0338(15)00178-8. doi: 10.1016/j.prp.2015.08.011. [Epub ahead of print] No abstract available.

PMID:
26839160
17.

Predominant role of spinal P2Y1 receptors in the development of neuropathic pain in rats.

Barragán-Iglesias P, Pineda-Farias JB, Bravo-Hernández M, Cervantes-Durán C, Price TJ, Murbartián J, Granados-Soto V.

Brain Res. 2016 Apr 1;1636:43-51. doi: 10.1016/j.brainres.2016.01.042. Epub 2016 Feb 2.

PMID:
26835558
18.

BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

Price TJ, Beeke C, Townsend AR, Lo L, Amitesh R, Padbury R, Roder D, Maddern G, Moore J, Karapetis C.

Mol Diagn Ther. 2016 Feb;20(1):75-82. doi: 10.1007/s40291-015-0179-7.

PMID:
26714964
19.

Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations.

Andrews NA, Latrémolière A, Basbaum AI, Mogil JS, Porreca F, Rice AS, Woolf CJ, Currie GL, Dworkin RH, Eisenach JC, Evans S, Gewandter JS, Gover TD, Handwerker H, Huang W, Iyengar S, Jensen MP, Kennedy JD, Lee N, Levine J, Lidster K, Machin I, McDermott MP, McMahon SB, Price TJ, Ross SE, Scherrer G, Seal RP, Sena ES, Silva E, Stone L, Svensson CI, Turk DC, Whiteside G.

Pain. 2016 Apr;157(4):901-9. doi: 10.1097/j.pain.0000000000000458.

20.

Optimal therapy for resectable rectal cancer.

Thavaneswaran S, Price TJ.

Expert Rev Anticancer Ther. 2016;16(3):285-302. doi: 10.1586/14737140.2016.1130627. Epub 2016 Jan 11.

PMID:
26652907
Items per page

Supplemental Content

Loading ...
Write to the Help Desk